Spots Global Cancer Trial Database for Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

Official Title: Randomized, Controlled Phase II Study of Valproic Acid in Patients With Non-metastatic Biochemical Progression of Prostate Cancer

Study ID: NCT00670046

Conditions

Prostate Cancer

Interventions

valproic acid

standard of care follow-up

Study Description

Brief Summary: RATIONALE: Valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether valproic acid is more effective than observation in treating patients with prostate cancer. PURPOSE: This randomized phase II trial is studying how well valproic acid works in treating patients with progressive, non-metastatic prostate cancer.

Detailed Description: OBJECTIVES: Primary * Assess whether treatment with valproic acid (a type I histone deacetylase inhibitor) can alter the kinetics of prostate-specific antigen (PSA) progression in patients with non-metastatic prostate cancer and biochemical progression. Secondary * Determine the duration of PSA response. * Assess the percentage of patients who achieve a complete response. * Assess the percentage of patients who achieve a partial response. * Assess the quality of life of these patients. OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 arms. * Arm I (observation): Patients undergo observation according to standard of care. * Arm II (valproic acid): Patients receive oral valproic acid twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.